Astellas Pharma Gmbh

Naomi Hosogai

Hiroki Shirai

Akifumi Morinaka

Kazunori Hirayama

Hitoshi Doihara

Daisuke Yamashita

Hiroyuki Moritomo

Takashi Sugane

Norio Asai

Keizo Sugasawa

Takafumi Shimizu

Yasuhiro Yonetoku

Kyoichi Maeno

Takuya Makino

Daisuke Tanabe

Hisashi Mihara

Kazuhiko Osoda

The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.

Anti-human MUC1 antibody Fab fragment

[Problem] To provide a compound useful as an MCreceptor agonist. [Means for Solution] The present inventors studied MCreceptor agonists, and have found that a piperazine derivative has an MCreceptor agonistic action, thereby completing the present invention. The piperazine derivative of the present invention has an MCreceptor agonistic action, and can be used as an agent for preventing or treating bladder and/or urinary tract diseases, in particular, underactive bladder, hypotonic bladder, acontractile bladder, detrusor underactivity, neurogenic bladder, urethral relaxation failure, detrusor-external urethral sphincter dyssynergia, and voiding dysfunctions in benign prostatic hyperplasia.

Piperazine derivative

Anti-human MUC1 antibody fab fragment

To provide a compound which can be used as an MCreceptor agonist. The present inventors have investigated MCreceptor agonists, and have found that a piperazine derivative has an action related to the agonists, thereby completing the present invention. That is, the piperazine derivative of the present invention has an MCreceptor agonistic action, and can be used as an agent for preventing or treating bladder and/or urinary tract diseases, in particular, underactive bladder, hypotonic bladder, acontractile bladder, detrusor underactivity, neurogenic bladder, urethral relaxation failure, detrusor-external urethral sphincter dyssynergia, and voiding dysfunctions in benign prostatic hyperplasia.

Growing community of inventors

Tokyo, Japan

Naomi Hosogai